Pancreatic polypeptide suppresses appetite through Y4 brain receptors and may protect insulin-producing cells, but its ultra-short half-life has prevented therapeutic development — long-acting analogs are needed.
Satiety in animals and humans via Y4Pancreatic polypeptide reliably induces satiety through a non-GLP-1 pathway (Y4 receptors), but breaks down too quickly for therapeutic use — engineering stable analogs could unlock a new obesity drug class
What the researchers found
Pancreatic polypeptide (PP) — a hormone released from the pancreas — suppresses appetite by activating Y4 receptors in the brain, producing satiety in both animals and humans. Beyond appetite control, PP also affects the insulin-producing beta cells of the pancreas, with an acute insulin-suppressing effect.
Intriguingly, sustained activation of related Y-family receptors (Y1) improves beta-cell survival, preserves beta-cell identity, and enhances insulin secretion — raising the possibility that long-acting Y4 agonists could provide similar anti-diabetic benefits. However, PP's extremely short half-life in the blood has prevented its therapeutic development. Engineering enzyme-resistant, long-acting versions will be necessary to test its clinical potential.
Why it matters
In the era of GLP-1 drugs, there's intense interest in other gut and pancreatic peptides that could combat obesity and diabetes. PP represents an underexplored pathway — it reduces appetite through a different receptor system (Y4) than GLP-1, and it may also protect beta cells. If long-acting PP analogs can be developed, they could complement or combine with existing GLP-1 drugs for enhanced metabolic benefits.
The numbers in context
PP activates Y4 receptors · induces satiety in animals + humans · acute insulinostatic effect · short circulating half-life (major limitation) · related Y1 activation improves beta-cell function
How the study worked
Narrative review synthesizing published preclinical and clinical evidence on PP biology, its receptor pharmacology (Y4R), its effects on appetite and the endocrine pancreas, and the challenges of therapeutic development. The authors draw parallels with related NPY family peptides and their receptor signaling pathways.
Who was studied
Review of preclinical and clinical literature on pancreatic polypeptide biology and therapeutics
What this study cannot tell us
This is a review — no new data presented. Much of the evidence for PP's metabolic effects comes from acute infusion studies in animals. Long-acting PP analogs have not yet been developed or tested, so the therapeutic potential remains theoretical. The comparison to Y1 receptor effects is inferential rather than proven for Y4.
How to read the evidence
This is a narrative review that synthesizes well-established PP biology with more speculative therapeutic implications. The satiety effects of PP are well-documented, but the anti-diabetic hypothesis is largely based on analogy with Y1 receptor data. No long-acting PP analogs have been tested, so the therapeutic potential remains unproven.
When this study was published
Published in 2023. The therapeutic landscape for metabolic peptides has continued to evolve rapidly. Whether long-acting PP analogs will be developed depends on pharmaceutical interest and the competitive pressure from increasingly effective GLP-1 and multi-agonist drugs.
The bigger picture
The success of GLP-1 drugs has sparked a gold rush for other appetite-regulating peptides. PP sits in a unique position — it's a well-known satiety hormone with established biology, but pharmaceutical development has been stalled by its short half-life. The same lipidation and PEGylation technologies that created semaglutide from native GLP-1 could potentially be applied to PP, creating a new class of Y4 receptor agonists for obesity and diabetes.
Questions still open
- Could a long-acting PP analog be combined with GLP-1 drugs for enhanced weight loss through dual-pathway appetite suppression?
- Does sustained Y4 receptor activation actually replicate the beta-cell protective effects seen with Y1 activation?
- Why has pharmaceutical interest in PP lagged so far behind GLP-1 despite similar biological promise?
Common questions
What is pancreatic polypeptide and where does it come from?
Why hasn't PP been developed into a drug like GLP-1?
Read the original research
Pancreatic polypeptide revisited: Potential therapeutic effects in obesity-diabetes.
Peptides, 160, 170923
Citation
Zhu, Wuyun; Tanday, Neil; Flatt, Peter R; Irwin, Nigel. (2023). Pancreatic polypeptide revisited: Potential therapeutic effects in obesity-diabetes.. Peptides, 160, 170923. https://doi.org/10.1016/j.peptides.2022.170923